Literature DB >> 2248982

Identification and initial characterization of a fourth leader exon and promoter of the human IGF-II gene.

P Holthuizen1, F M van der Lee, K Ikejiri, M Yamamoto, J S Sussenbach.   

Abstract

Transcription of the human insulin-like growth factor II (IGF-II) gene is regulated by activation of multiple promoters which act in a tissue-specific and development-dependent manner. Previously, we have identified three different promoters, one of which is active in adult liver tissue only, whereas the other two are active in many fetal tissues and adult non-hepatic tissues. Here we report the identification of a fourth leader exon of the human IGF-II gene indicating the presence of a fourth promoter. Transcription from this promoter yields a 5.0 kb IGF-II mRNA species, which is detected in fetal liver and leiomyosarcoma tissue.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2248982     DOI: 10.1016/0167-4781(90)90010-y

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  23 in total

Review 1.  Molecular biology of the insulin-like growth factors. Relevance to nervous system function.

Authors:  J E Hepler; P K Lund
Journal:  Mol Neurobiol       Date:  1990 Spring-Summer       Impact factor: 5.590

2.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1991-06-25       Impact factor: 16.971

3.  The retinoblastoma gene product regulates Sp1-mediated transcription.

Authors:  S J Kim; U S Onwuta; Y I Lee; R Li; M R Botchan; P D Robbins
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

4.  Identification of a key regulatory element for the basal activity of the human insulin-like growth factor II gene promoter P3.

Authors:  L E Rietveld; P E Holthuizen; J S Sussenbach
Journal:  Biochem J       Date:  1997-11-01       Impact factor: 3.857

Review 5.  Beckwith-Wiedemann syndrome and the insulin-like growth factor-II gene. Does the genotype explain the phenotype?

Authors:  D P Witte; K E Bove
Journal:  Am J Pathol       Date:  1994-10       Impact factor: 4.307

6.  Development of targeted therapy for a broad spectrum of cancers (pancreatic cancer, ovarian cancer, glioblastoma and HCC) mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences.

Authors:  Doron Amit; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2012-08-22

7.  Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P3 and IGF2-P4 regulatory sequences.

Authors:  Doron Amit; Sagi Tamir; Tatiana Birman; Ofer N Gofrit; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2011-04-30

8.  A conserved structural element in horse and mouse IGF2 genes binds a methylation sensitive factor.

Authors:  K Otte; D Choudhury; M Charalambous; W Engström; B Rozell
Journal:  Nucleic Acids Res       Date:  1998-04-01       Impact factor: 16.971

9.  DNA polymorphisms in the human tyrosine hydroxylase/insulin/insulin-like growth factor II chromosomal region in relation to glucose and insulin responses.

Authors:  M Sten-Linder; A Wedell; L Iselius; S Efendic; R Luft; H Luthman
Journal:  Diabetologia       Date:  1993-01       Impact factor: 10.122

10.  Site-specific cleavage of IGF-II mRNAs requires sequence elements from two distinct regions of the IGF-II gene.

Authors:  D Meinsma; W Scheper; P E Holthuizen; J L Van den Brande; J S Sussenbach
Journal:  Nucleic Acids Res       Date:  1992-10-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.